Try our Advanced Search for more refined results

Tevra Brands LLC v. Bayer HealthCare LLC, et al

Track this case

Case overview

Case Number:

5:19-cv-04312

See also:

Court:

California Northern

Nature of Suit:

Anti-Trust

Judge:

Beth Labson Freeman

Firms

Companies

Sectors & Industries:

  1. September 15, 2025

    Bayer Urges 9th Circ. Not To Revive Tevra Flea, Tick Meds Suit

    Bayer is urging the Ninth Circuit not to grant a new trial over claims that it locked up the market for pet flea and tick treatment, saying the only evidence that rival Tevra showed a jury at trial was "highly dubious."

  2. July 14, 2025

    Tevra Asks 9th Circ. To Revive Bayer Flea, Tick Meds Suit

    Tevra Brands LLC called on the Ninth Circuit to order a new trial after it said a lower court made several errors that prevented it from showing a jury that Bayer HealthCare LLC used exclusive contracts to lock up the market for a flea and tick treatment for dogs and cats.

  3. January 22, 2025

    No New Trial For Tevra's Flea, Tick Meds Suit Against Bayer

    A California federal judge refused to give Tevra Brands LLC a do-over on allegations that Bayer used exclusive contracts to anticompetitively lock up the market for flea and tick treatments for dogs, finding the veterinary drugmaker was just rehashing previously rejected arguments attacking a key expert witness.

  4. August 01, 2024

    Calif. Jury Clears Bayer In Flea And Tick Med Antitrust Suit

    A California federal jury on Thursday cleared Bayer of allegations that it owes millions for cutting anticompetitive deals with pet product retailers to undermine competition from generics makers of flea and tick treatments for dogs.

  5. July 22, 2024

    Tevra Says Bayer Owes Millions As Antitrust Trial Opens

    Tevra Brands LLC told a California federal jury during antitrust trial openings Monday that Bayer owes millions of dollars for allegedly cutting anticompetitive deals with retailers to undermine competition from anti-flea-and-tick treatment generics, while Bayer defended its "reasonable" and optional retailer discounts and criticized Tevra's "astronomical" damages demand.

  6. May 01, 2024

    Bayer Can't Scratch Off Antitrust Suit Over Flea, Tick Meds

    A California federal judge has largely declined Bayer's bid to dismiss generics competitor Tevra's pet medication antitrust suit, saying in an order released Wednesday that there are factual disputes about whether Bayer's exclusivity deals with distributors and retailers significantly foreclosed Tevra's potential sales in the market.

  7. May 03, 2021

    Bayer Wants To Shake Off Flea & Tick Drugs Antitrust Suit

    Bayer HealthCare LLC and a former subsidiary are seeking to escape pet medication company Tevra Brands LLC's $114 million antitrust suit for flea and tick treatment products, arguing that Tevra's proposed market argument is "fatally flawed because it fails to include all reasonably interchangeable products."

  8. July 30, 2020

    Bayer Antitrust Judge Fears Opening Discovery 'Floodgates'

    A California federal judge expressed "a lot of concerns" Thursday about the adequacy of Tevra Brands LLC's $114 million pet medication antitrust complaint against Bayer, saying she's hesitant to "open up the floodgates of what will be enormously expensive discovery."

  9. June 23, 2020

    Bayer Foe Blocked From Serving Docs Via Email Amid Virus

    A California federal judge overseeing a $114 million antitrust case against U.S.-based Bayer HealthCare LLC ruled Tuesday that the COVID-19 pandemic isn't enough reason to allow the generic pet medication company that brought the suit to serve Bayer's German parent company via email.

  10. June 01, 2020

    Bayer Slams Pet Med Co.'s Bid To Serve Docs Via Email

    Bayer HealthCare urged a California federal court against allowing a generic pet medication maker to flout international protocol for how to serve documents in a $114 million antitrust case, saying the company is trying to use the COVID-19 pandemic as a scapegoat for its own delays and errors.